![Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial | Nature Medicine Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-023-02347-y/MediaObjects/41591_2023_2347_Fig1_HTML.png)
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial | Nature Medicine
![Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy | Nature Communications Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-020-20688-x/MediaObjects/41467_2020_20688_Fig1_HTML.png)
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy | Nature Communications
Mectronic Medicale - ๐ด๐ โ๐๐โ-๐ก๐๐โ ๐๐๐ฃ๐๐๐, ๐๐๐ ๐๐๐๐๐ ๐ก๐ ๐๐๐๐๐ ๐กโ๐ ๐กโ๐๐๐๐๐๐ ๐ก ๐๐๐ ๐กโ๐ ๐ก๐๐๐๐ ๐๐๐ ๐ ๐๐๐๐ฅ๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐ก๐๐ฃ๐ ๐กโ๐๐๐๐๐ฆ: ๐ถ๐๐๐ ๐ฃ๐๐จ๐ฆ! Designed and built entirely ...
![The geography of COVID-19 spread in Italy and implications for the relaxation of confinement measures | Nature Communications The geography of COVID-19 spread in Italy and implications for the relaxation of confinement measures | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-020-18050-2/MediaObjects/41467_2020_18050_Fig1_HTML.png)
The geography of COVID-19 spread in Italy and implications for the relaxation of confinement measures | Nature Communications
![Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-023-02321-8/MediaObjects/41591_2023_2321_Fig1_HTML.png)
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine
![Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ... Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...](https://www.thelancet.com/cms/asset/a8001e13-49e3-44c0-b050-179d0a0a5858/gr1.jpg)
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...
![Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/209b827d-c7bc-4235-8c71-c999e28e9c68/gr1.jpg)
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology
![Tracing the mobility of a Late Epigravettian (~ 13 ka) male infant from Grotte di Pradis (Northeastern Italian Prealps) at high-temporal resolution | Scientific Reports Tracing the mobility of a Late Epigravettian (~ 13 ka) male infant from Grotte di Pradis (Northeastern Italian Prealps) at high-temporal resolution | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-12193-6/MediaObjects/41598_2022_12193_Fig1_HTML.png)